Kaken Pharmaceutical
Kaken Pharmaceutical Co Ltd is a Japanese pharmaceutical company developing, manufacturing, and marketing prescription drugs, medical devices, and agrochemicals. The company specializes in dermatology, orthopedics, and infectious disease treatments, producing flagship products such as Jublia (efinaconazole) for onychomycosis and Artz intra-articular hyaluronic acid injections for osteoarthritis. Principal revenues derive from direct product sales of prescription pharmaceuticals and medical devices to hospital networks, medical wholesalers, and pharmacies across Japan and international markets through licensing partners. Core end markets encompass orthopedic clinics, dermatology practices, clinical hospital departments, and prescription patients in Japan, North America, and Europe. Kaken Pharmaceutical holds a market-leading domestic position in Japan for topical antifungal and joint health treatments. The company is headquartered in Tokyo, Japan, and its common stock trades on the Prime Market of the Tokyo Stock Exchange.
2 of the funds FundTelligence covers report a position in Kaken Pharmaceutical.
- Legal name
- Kaken Pharmaceutical Co Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 2
Funds holding Kaken Pharmaceutical
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)